LONDON (ShareCast) - (Sharecast News) - Internet of Things investor Tern said on Tuesday that Talking Medicines, in which it currently holds a 23.8% equity share, has made "a strong start to 2024", marked by record revenue bookings and significant advancements in its Talking Medicines Drug-GPT platform.
During Q1, Talking Medicines said it had achieved "significant success" with its Talking Medicines Drug-GPT platform, with the technology garnering "substantial interest" from leading global healthcare advertising agencies.

Additionally, Talking Medicines noted it had forged strategic partnerships with both open and closed data communities, solidifying its commitment to expanding access to crucial insights. Notable among these partnerships was its collaboration with data aggregator Socialgist, which enables Talking Medicines to tap into millions of public conversational sites, enriching the Talking Medicines Drug-GPT platform with "a wealth of diverse data sources".

Talking Medicines chief executive Jo Halliday said: "We are thrilled by the broad response to Talking Medicines Drug-GPT and our strategic partnerships. This success underscores our dedication to empowering healthcare stakeholders with actionable insights derived from advanced data science and artificial intelligence."

Looking ahead, Talking Medicines stated it "remains committed" to driving innovation and fostering collaborations that enhance healthcare decision-making through intelligence globally.

As of 1030 BST, Tern shares had surged 14.03% to 3.54p.







Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE